Vivani Medical announced it has raised $10 million in equity financing to advance its NanoPortal drug delivery technology. The Alameda-based firm develops implants designed to deliver steady medication doses over extended periods, reducing safety risks from fluctuating drug release profiles. The technology can deliver large hydrophilic molecules such as peptides and proteins, enabling a wider range of therapeutic uses. In March, Vivani reported the first successful administration of a GLP-1 implant in its LIBERATE-1 clinical trial. The latest funding comes from the sale of nearly 8 million shares of common stock at $1.26 each. Proceeds are expected to secure the company’s financial position through the second half of 2026. The funds will support prioritizing and accelerating the development of NPM-139, a semaglutide implant, into clinical trials targeted for 2026. Board chair Gregg Williams said the financing reflects confidence in NanoPortal implants and management’s ability to deliver transformative treatments for chronic diseases. CEO Adam Mendelsohn highlighted positive LIBERATE-1 results, showing safety and tolerability for NPM-115, and promising preclinical data for NPM-139 indicating sustained 20% weight loss for over six months. Vivani expects to provide a detailed update on the NPM-139 programme later this year. The company plans to spin off its Cortigent brain implant division in late 2025. Strategic focus on NPM-139 is seen as enhancing both technical success prospects and commercial potential in the growing semaglutide-based treatment market.